Insmed (NASDAQ:INSM) stock is rising higher on Tuesday after the company announced positive results from a Phase 3 clinical trial of brensocatib in patients with non-cystic fibrosis bronchiectasis. This saw brensocatib reach its primary endpoint of statistically significant reductions in the annualized rate of pulmonary exacerbations (PEs) versus placebo. In addition to that, the study also met several of its secondary endpoints. James Chalmers, MBChB, Ph.D., Professor and Consultant Respiratory Physician a ...

—Phase 3 Study Achieves Primary Endpoint for Both Dosage Strengths of Brensocatib with Statistically Significant and Clinically Meaningful Reduction in Frequency of Pulmonary Exacerbations Versus Placebo— BRIDGEWATER, N.J., May 28, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced positive topline results from the ASPEN study, a global, randomized, double-blind, placebo- ...

BRIDGEWATER, N.J., May 27, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will host a conference call and webcast tomorrow, Tuesday, May 28, 2024, at 8:00 am ET to discuss topline results from the ASPEN study, a global, randomized, double-blind, placebo-controlled Phase 3 study to assess the efficacy, safety, and tolerability of brensocatib in patients with non ...

Insmed (INSM) reported a loss of $1.06 per share in the first quarter of 2024, narrower than the Zacks Consensus Estimate of a loss of $1.22. In the year-ago quarter, the company posted a loss of $1.17.Insmed generated total revenues of $75.5 million during the quarter, which were up 16% year over year. The reported sales missed the Zacks Consensus Estimate of $78.9 million.Quarter in DetailIn the reported quarter, total revenues were generated entirely from product revenues of Insmed’s only marketed drug, ...

Insmed, Inc. (NASDAQ:INSM) Q1 2024 Earnings Conference Call May 9, 2024 8:00 AM ET Company Participants Bryan Dunn - Executive Director, Investor Relations William Lewis - Chairman, President & CEO Eugene Sullivan - Chief Product Strategy Officer & Chief Scientific Officer Sara Bonstein - CFO Conference Call Participants Andrea Tan - Goldman Sachs & Co. Jessica Fye - JPMorgan Securities Leon Wang - Barclays Capital Joseph Schwartz - Leerink Partners Nicole Germino - Truist Securities Jason Zemansky - Bank o ...

For the quarter ended March 2024, Insmed (INSM) reported revenue of $75.5 million, up 15.8% over the same period last year. EPS came in at -$1.06, compared to -$1.17 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $78.88 million, representing a surprise of -4.28%. The company delivered an EPS surprise of +13.11%, with the consensus EPS estimate being -$1.22.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how the ...

Insmed (INSM) came out with a quarterly loss of $1.06 per share versus the Zacks Consensus Estimate of a loss of $1.22. This compares to loss of $1.17 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 13.11%. A quarter ago, it was expected that this biopharmaceutical developing inhaled treatments for patients battling rare lung diseases would post a loss of $1.13 per share when it actually produced a loss of $1.28, delivering a ...

Exhibit 99.1 Insmed Reports First-Quarter 2024 Financial Results and Provides Business Update — ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $75.5 Million for the First Quarter of 2024, Reflecting 16% Annual Growth Over the First Quarter of 2023— —Company Reports Positive Topline Safety and Tolerability Data from the Phase 2 PH-ILD Study of TPIP with 79.3% of Patients Reaching the Maximum Dose of 640 µg by Week 5, with an Unexpectedly Positive and Robust Signal on the Exploratory End ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-30739 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 54-1972729 (State or other jurisdictio ...

Investors are always looking for stocks that are poised to beat at earnings season and Insmed Incorporated (INSM) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.That is because Insmed is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings — with the most up-to-date information possible — is a pretty good in ...